FDA Approves Rinvoq for Active Psoriatic Arthritis

By SPC News Staff

The FDA approved upadacitinib (Rinvoq, AbbVie) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.